CNBC – RFK Jr.’s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims stock price growth 25% since the peptide meeting day is set KEY POINTS Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited. The …